Welcome to the Inaugural Liquid Biopsy for Precision Medicine Summit Europe!
Over the last year, disease diagnosis has taken significant strides due to investment, collaborations and technology advances of liquid biopsies, including a world-first blood test for brain cancer that experts say could revolutionise diagnosis, speed up treatment and boost survival rates.
This is due to their ability to detect disease before symptoms emerge and is thus becoming a growing interest to European biopharma and diagnostic developers, but critical hurdles need to be overcome for this to become a reality for patients.
Enter the Liquid Biopsy for Precision Medicine Summit Europe—a ground-breaking summit designed to tackle key challenges, from conceptualization to commercialization and pioneer the widespread adoption of liquid biopsy tests in Europe to bring personalized treatments to patients in oncology, neurology, rare diseases, and beyond.
This summit is your prime opportunity to participate in the ONLY industry-led event dedicated to catalysing a meaningful shift inresponse monitoring, relapse detection, dose optimization, and more, using sensitive and robust liquid biopsy tests for patients in need.
FULL AGENDA
World-Class Speaker Faculty
David Weingeist
Scientific Director, Oncology Precision Medicine & Diagnostics
Johnson & Johnson Innovative Medicine
Take your seat in the room to:
Delve into the learnings from oncology to neuroscience and rare disease to provide more personalised treatment options for patients and improve outcomes, with insights from TauRx Therapeutics and the Brain Tumour Research Centre of Excellence at Imperial College London
Expand your knowledge of dose optimization by walking through liquid biopsy biomarker data demonstrating mode of action, safety and clinical efficacy to develop learnings from a t-cell bispecific molecule with insights from AstraZeneca
Unravel the complexities around expanding the application of liquid biopsies beyond last resort approaches by overcoming the challenges associated with IVDR and reimbursement and increase routine commissioning with insights from Step Pharma and Janssen Pharmaceuticals
What our speakers have to say:
A cross-sector approach is key to mobilising ctDNA analysis for cancer patients and democratising access to testing. By bringing people from different disciplines together, this meeting acts as a facilitator on this important path. - Philip Beer, Chief Scientific Officer
